SEC Form 4 · accession 0001127602-15-011504
BIOGEN INC. · BIIB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George A Scangos
Officer — Chief Executive Officer · Director
Period of report
Mar 13, 2015
Accepted (ET)
Mar 16, 2015 · 8:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875045
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Mar 13, 2015 | S | 537 | $412.688 | D | 45,176 | D | |
| Common Stock | holding | — | — | — | 5,378 | I | by Trust | |
| Common Stock | holding | — | — | — | 5,378 | I | by Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- F2Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- F3This represents the weighted average price for shares sold at a range between $412.63 (low) and $412.76 (high).